However, supply of Helixate FS will continue to be available through early 2019. We recognize that Helixate FS has been an important part of your patients' lives, and hope we can be of assistance as you consider alternatives.
We’ve created an FAQ document with additional details.Download the FAQ
As a patient-focused company, CSL Behring strives to create innovative therapies for the hemophilia community. That’s why we’ve developed long-lasting AFSTYLA, a next-generation Factor VIII therapy.
With twice-weekly dosing available,* AFSTYLA is the first and only recombinant Factor VIII that delivers proven, long-lasting bleed protection with a novel single-chain design. AFSTYLA also delivered zero bleeds (median AsBR†) in all studied populations regardless of dosing regimen. Take a moment to explore all that AFSTYLA can offer your patients.
All the support services and the reconstitution system your patients have come to rely on and trust with Helixate FS will remain in place for patients taking AFSTYLA. Services‡ include:
At My Source for AFSTYLA, your patients can get help with financial support and learn more about hemophilia A.
My Source Care Coordinators are standing by to help.
Monday–Friday, 8 am to 8 pm ET
Get your patients a free one-month trial to see if AFSTYLA is right for them. In case of coverage delays, your patients may receive another one-month trial of AFSTYLA. Print and fill out the AFSTYLA Patient Referral Form.
My Source for AFSTYLA can help your eligible patients get co-pay assistance and financial support. Visit AFSTYLA.com/support for more details.